Novolizer (Budesonide)

Budesonide, the active ingredient in Novolizer, is a corticosteroid presented as a dry‑powder inhaler for inhalation use. It reduces airway inflammation and is used for long‑term management of asthma and chronic obstructive pulmonary disease. GNH USA supplies Novolizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novolizer delivers budesonide to the airways, targeting inflammatory respiratory conditions.

- Asthma: improves symptom control and reduces exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases frequency of flare‑ups. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Inhaled budesonide may cause a range of local and systemic reactions.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth. - Hoarseness: voice changes after inhalation. - Throat irritation: mild discomfort or soreness. - Cough: transient irritation of the airway. - Headache: mild to moderate intensity. - Upper respiratory tract infection: nasopharyngitis.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: especially in patients with COPD. - Severe allergic reaction: anaphylaxis or angioedema. - Growth retardation in children: potential impact on height development. - Paradoxical bronchospasm: sudden worsening of breathing.

Before prescribing Novolizer, consider the following safety measures.

- Assess infection risk: evaluate for active respiratory infections. - Monitor growth in children: regular height checks are recommended. - Avoid abrupt discontinuation: taper if long‑term systemic exposure is suspected. - Use mouth rinse after inhalation: reduces risk of oral candidiasis. - Check for hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Budesonide may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide exposure. - Ritonavir: potent CYP3A4 inhibition leading to higher corticosteroid levels. - Systemic corticosteroids: additive immunosuppressive effects. - Live vaccines: reduced efficacy and increased infection risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise budesonide levels. - Macrolide antibiotics (e.g., erythromycin): potential increase in systemic exposure. - Diuretics: may enhance risk of hypokalemia when combined with systemic steroids.